The Australian today

Feel good story - but all helps to get the message out there.

Not sure about 'almost doubling the rate of tumour shrinkage and remission in patients'.

http://www.theaustralian.com.au/bus...the-biotech-dice/story-e6frgabx-1227090406491

Sydney-based Sirtex has developed technology to deliver radiation therapy for patients terminally ill with liver cancer. It can’t cure cancer but its “microsphere”, or small-particle technology, is extending lives, almost doubling the rate of tumour shrinkage and remission in patients. Doctors can target tumours with the Sirtex product more accurately than with traditional methods. Its share price has taken off, from about $4 in 2012 to more than $20 this year.
But it was a very different story in 2004 when the company was running out of money. Gilman Wong was involved in business-building and marketing in the whitegoods industry, before he was approached in 2005 to run Sirtex. Wong laughed when a recruiter suggested he could run Sirtex. Listed in 2000, the company was losing $1.5 million a year and had just $6m left in the bank.
Management was too “heavily weighted on the technical side, the science side”, says Wong who took over as chief executive in 2005. He says it had a product which was effective but it was too expensive. Addressing costs in the manufacturing process and across the business underpinned Wong’s turnaround strategy. “There have been no red numbers since, and we have grown our cash balance (to $52m),” he says. “Our market cap 10 years ago was $50m which has climbed to over $1 billion today,” Wong says.